UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~PURSUANT~~Pursuant TOto ~~SECTION~~Section 13 ORor 15(d) OFof the Securities Exchange Act of 1934

~~THE~~Date ~~SECURITIES~~of ~~EXCHANGE~~Report ~~ACT~~(Date OFof ~~1934~~earliest event reported): April 27, 2015

~~Date of Report (Date of earliest event reported): April 1, 2015~~000-55149

Commission File Number

AV Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	~~000-55149~~	33-1222799
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)
600 Third Avenue, Suite 350 New York, NY		10016
(Address of principal executive offices)		(Zip Code)

20Check ~~East~~the ~~68th~~appropriate ~~Street,~~box ~~Suite~~below ~~204~~if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

New York, NY 10065

(Address of principal executive offices) (zip code)

917-497-5523

(Registrant's telephone number, including area code)

____________

(Former name, if changed since last report.)

Copies to:

Darrin M. Ocasio, Esq.

Jeff Cahlon, Esq.

Sichenzia Ross Friedman Ference LLP

61 Broadway

New York, New York 10006

Phone: (212) 930-9700

Fax: (212) 930-9725

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~ITEM 45.0102 ~~Changes~~Departure inof ~~Registrant’s~~Directors ~~Certifying~~or ~~Accountant.~~Certain Officers; Election of Directors, Appointment of Certain Officers, Compensatory Arrangements of Certain Officers

~~On April 1, 2015, Marcum LLP~~ (~~“Marcum”~~b) ~~was~~Effective ~~dismissed~~June ~~as the independent registered public accounting firm of AV Therapeutics~~22, ~~Inc. (the “Company”). Marcum’s audit report on the Company’s financial statements for the years ended December 31~~2015, ~~2013~~Robert ~~and~~Pollock ~~2012~~resigned ~~did~~his ~~not~~positon ~~contain an adverse opinion or a disclaimer of opinion and was not qualified or modified~~ as ~~to uncertainty, audit scope or accounting principles, except that, the audit report included an explanatory paragraph with respect to the uncertainty as to the~~ Company’s ~~ability to continue as a going concern~~President. During the years ended December 31, 2014 and 2013 and during the subsequent interim period preceding the date of Marcum’s dismissal, there were (i) no disagreements with Marcum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, and (ii) no reportable events (as that term is defined in Item 304(a)(1)(v) of Regulation S-K), other than (i) Marcum advised the Company of material weaknesses in the Company’s internal control over financial reporting, which identified weaknesses were reported in Item 9A in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.

On(c) ~~April~~Effective 1June 22, 2015, ~~the~~Abraham ~~Company engaged Accell Audit and Compliance~~Mittelman, PM.AD. ~~(“Accell”) to serve as its independent registered public accounting firm. During the years ended December 31~~, ~~2014 and 2013 and during~~ the ~~subsequent interim period preceding the date of Accell~~Company’s ~~engagement,~~CEO ~~the~~assumed ~~Company did not consult with Accell regarding~~ the ~~application~~duties ofas ~~accounting principles to a specific completed or contemplated transaction, or~~ the ~~type of audit opinion that might be rendered on the~~ Company’s ~~financial statements~~President. ~~The decision to dismiss Marcum and engage Accell was approved by the Company’s board of directors.~~

~~The~~(d) ~~Company~~On ~~has~~April ~~requested~~27, ~~Marcum~~2015, ~~to furnish it with a letter addressed to~~ the ~~SEC~~Board ~~stating~~of ~~whether~~Directors ~~it agrees with~~ (the ~~statements~~“Board”) ~~made~~appointed Robert ~~above~~K. byGardner to the Company.’s ~~The Company has filed this letter as an exhibit to this 8-K~~Board.

~~Item~~Robert 9K.01 ~~Financial~~Gardner ~~Statements~~is the founding member of New World Technology Partners (“NWTP”) and ~~Exhibits~~has been a leader in “strategic” technology development and an incubator of technology enterprises since the mid-seventies. He has managed and participated in the launch of several development stage companies, including August Systems, Verdix, Meiko Scientific, Cryptek, Phoenix Numeric and Probity Labs. He also led turnarounds of public companies, including General Kinetics and Verdix Corp. At a mid-cap Department of Defense service provider, he created an intellectual property incubator which introduced Trusted TeamWorks™ and several Machine-vision innovations. He recently led the development of the iRISK™ enterprise risk management methodology. Prior to forming NWTP, he held senior engineering and technical marketing positions for Burroughs Corporation’s Supercomputer activities, including ILLIAC IV, PEPE, LDSP and NASF, for which he received both technical and sales accolades and awards. Mr. Gardner has a BSEE from Rensselaer Polytechnic Institute and studied graduate system engineering and business administration at Penn State and the University of Santa Clara respectively. He writes and speaks on topics regarding intellectual property and has prepared briefings and testimony for the U.S. House of Representatives and Senate committees and caucuses.

~~(d)~~In ~~Exhibits~~consideration of Mr. Gardner agreeing to become a director of the Company, at his direction, the Board has agreed to issue to NWTP, three million shares of the Company’s common stock.

Exhibit Number		Description
16.1		Letter from Marcum

Item 7.01 Regulation FD Disclosure

On June 25, 2015, the Company will deliver a presentation to members of the financial community at the National Investment Banking Association in Newport Beach, CA. The slides to be used at the meeting are furnished herewith as Exhibit 99.1 and are incorporated by reference into Item 7.01 of this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be deemed to be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

ITEM 8.01 Other Events

Relocation of Executive Offices

The Company has moved its executive offices from 20 East 68th Street, Suite 204, New York, NY 10065 to 600 Third Avenue, Suite 350, New York, NY 10016

Item 9.01 Financial Statements and Exhibits

Number		Exhibit
99.1		Investor Presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the ~~registrant~~Registrant has duly caused this report to be signed on its behalf by the undersigned ~~hereunto~~thereunto duly authorized.

	AV THERAPEUTICS, INC.
Dated: April 7, 2015	By:	/s/ Abraham Mittelman
Date: June 25, 2015	By:	/s/ Abraham Mittelman
		Name: Abraham Mittelman
	Name:	Abraham Mittelman
		Title: Chief Executive Officer
	Title:	CEO

Filing Compare · AV Therapeutics, Inc.